PDS Biotechnology Corp（PDSB）の株式分析PDSBPDS Biotechnology Corp

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PDS Biotechnology Corp is currently not a strong buy due to its recent performance and financial instability. The current price is $1.11, with a 5-day change of -1.77% and a 20-day change of +39.25%. However, the company has significant net losses, with a net income of -$9.75 million in Q2 2026, and a current ratio that dropped to 0.57, indicating potential liquidity issues. While the stock has shown some positive momentum, the risks associated with its financial health suggest a hold rather than a buy at this time.